Together Pharma Ltd.
TTASE:TGTR201.20
ILA
+0.10
(+0.05%)
ISIN
IL0004620105
Return %
Stock
S&P 500
1Y
-41.75
14.20
3Y
-26.35
81.12
5Y
-85.55
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Semi-annual Revenue
FRC
•
in mil. unless spec.Semi-annual Earnings Per Share
FRC
•
in mil. unless spec.Semi-annual Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Nissim Bracha
- Full Time Employees
- 95
- Sector
- Health technology
- Industry
- Pharmaceuticals: other
- Address
- Globus Center Complex Ashkelon HD Israel 7810001
- IPO Date
- May 1, 1993
- Website
- together-pharma.com
- Similar Companies
- Business
- Together Pharma Ltd (TASE: TGTR) engages in the cultivation, production, manufacturing, storage, and distribution of medical cannabis products through its subsidiaries, primarily Globus Pharma Ltd, in Israel. The company offers a comprehensive range of core products including dried cannabis flowers in various strains such as high-THC genetics like Glueberry OG and Power Plant; value-for-money (VFM) cannabis products; premium exclusive solutions; and pharmaceutical-grade formulations produced in clean rooms compliant with Israel's IMC-GAP standards for medical use. Operations encompass advanced greenhouse cultivation controlled by agronomists and state-of-the-art systems for breeding, growing, and processing cannabis to meet strict Ministry of Health requirements, with distribution networks supporting pharmacy delivery in Israel under GDP-IMC standards and readiness for international exports. Headquartered in Ashkelon, Israel, and originally incorporated in 1991, Together Pharma maintains facilities including a pharmaceutical factory adaptation for manufacturing and partnerships for global expansion, such as supplies from Ugandan greenhouses exporting to Europe via collaborations like Cantourage for markets in Germany and the UK. Recent developments include ongoing setup of one of the world's most advanced agricultural cultivation systems using cutting-edge technologies for plant supervision; adaptation of a pharmaceutical factory to IMC-GAP standards; a NIS 192.5 million supply deal with Canna-Tech for at least five tons of annual medical cannabis production over five years at NIS 5.50 per gram; and strategic alliances with international partners like Cantourage to introduce Ugandan-grown products into European markets, alongside reported preliminary Q3 2024 revenues of 23.4 million shekels.